Optiscan Imaging (ASX:OIL) has signed an exclusive three-year distribution agreement in North America for its preclinical research system, ViewnVivo.
The agreement has been executed with Canada based Scintica Instrumentation Inc, with the option to extend the agreement for another two years.
Optiscan is a manufacturer of high-resolution miniaturised confocal endomicroscopes (instrument to view submicron resolution images in detail) for clinical and preclinical research markets.
Optiscan will benefit from Scintica’s market expertise, direct sales coverage, distribution and product support across the North American preclinical research markets.
The company will work closely with Scintica to support the existing Optiscan customer base and a number of potential new customers in the U.S. that are currently trialling the new ViewnVivo system.
Optiscan and Scintica will work on joint marketing plans including Optiscan committing to a significant presence at the World Molecular Imaging Congress (WMIC) to be held in Philadelphia in September.
WMIC represents an opportunity to showcase the ViewnVivo technology directly to the opinion leaders in the preclinical research market and accelerate the take-to-market strategy in North America.
In May, Optiscan installed two ViewnVivo systems in high profile research facilities in the U.S for customer experiments, demonstrations, validation and specific research application testing.
It is expected that both these installations will convert to sales.